Clinical trial · Observational
Lenalidomide Adherence in Older Adults
Lenalidomide Adherence in Older Adults: A Pilot Prospective Cohort Study of Oral Therapy for Multiple Myeloma
NCT03779555CI-TRIAL-00047804terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Principal Investigator left the university
Summary
Brief summary (as posted)
To describe patterns of adherence and pilot baseline measures to investigate factors associated with lower adherence to lenalidomide in older adults with myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Medication Event Monitoring System | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients taking lenalidomide for multiple myeloma
- description
- -Patients will be seen at baseline, 1 month (+/- 1 week), 2 months (3-5 weeks following 1-month assessment), and 3 months (3-5 weeks after 2-month follow-up)
- interventionNames
- Other: Medication Event Monitoring System
Primary outcomes (1)
- measure
- Adherence rate as measured by the number of days in which the lenalidomide pill bottle was open
- timeFrame
- Through completion of study (estimated to be 3 months)
- description
- -Participants will be given a pill diary in which they will record if they opened the pill bottle without taking a medication (e.g. to ascertain remaining supply) to adjust the adherence rate accordingly
Secondary outcomes (1)
- measure
- Adherence rate as measured by a modified Brief Adherence Rating Scale
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥65 * Receiving lenalidomide for treatment of multiple myeloma. * Anticipated to receive ongoing care at Siteman Cancer Center and its satellite sites * Able to read and understand English. * Able to understand and willing to sign an IRB-approved written informed consent document. Exclusion Criteria: * Estimated life expectancy \<6 months. * Anticipated duration of lenalidomide therapy \<3 months. * Residing in a nursing facility where their medications are administered to them OR patient reports they do not self-administer their own medications.
References
Publications (1)
- DERIVEDSilberstein AE, Fiala MA, Loh KP, Cordner T, Mian H, Wildes TM. A pilot study of adherence to lenalidomide among older patients with multiple myeloma. J Geriatr Oncol. 2023 Sep;14(7):101560. doi: 10.1016/j.jgo.2023.101560. Epub 2023 Jun 27. No abstract available. PMID 37380519